# Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

> **NCT00488319** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 400 (actual)

## Conditions studied

- Schizophrenia
- Schizophrenic Disorders
- Psychotic Disorders
- Dementia Praecox

## Interventions

- **DRUG:** Paliperidone ER

## Key facts

- **NCT ID:** NCT00488319
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488319, "Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00488319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*